The FDA granted orphan drug designation to HLX22 for gastric cancer, advancing global phase 3 trials to improve first-line ...

SHANGHAI, March 19, 2025 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for HLX22, the ...

近年来，单克隆抗体药物已广泛应用于多种疾病的治疗，大家是否注意过，它们的名字中多有「珠」、「昔」、「利」、「妥」等字样，那么这些在单克隆抗体的名字中常常出现的字有什么特殊的含义吗？《对我国单克隆抗体类药物通用名称命名的建议》一文中提到，我国单克隆抗体 ...

I-Mab (IMAB) stock gains as an early-stage trial for its gastric cancer therapy givastomig advances in a faster than expected ...

Antibody mAb 3A6 takes advantage of this little protein dance. It has such a strong affinity for its viral target that it can slip between the proteins, lift them up, and latch onto its target.

The Breez 2 mL micro-bioreactor platform is a fully automated, functionally closed, and continuous perfusion cell culture ...

I-Mab has completed enrollment ahead of schedule in the first cohort of its Phase 1b dose expansion study, which evaluates the bispecific antibody givastomig for treating gastric cancer.

The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T ...

The firm completed enrollment of the first dose expansion cohort evaluating givastomig with immunotherapy and chemotherapy.

I-Mab (IMAB) announced that enrollment has been completed ahead of schedule in the first dose expansion cohort in the Phase 1b givastomig ...

March 07, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB ... x 4-1BB bispecific antibody, targeting CLDN18.2-expressing tumor cells for the treatment of gastric cancer in the first-line (1L ...